165 related articles for article (PubMed ID: 37676829)
1. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract][Full Text] [Related]
2. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E; Paré L; Schettini F; Martínez D; Jares P; Griguolo G; Dieci MV; Cortés J; Llombart-Cussac A; Conte B; Marín-Aguilera M; Chic N; Puig-Butillé JA; Martínez A; Galván P; Tsai YH; González-Farré B; Mira A; Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM
EBioMedicine; 2022 Jan; 75():103801. PubMed ID: 34990895
[TBL] [Abstract][Full Text] [Related]
4. Metastatic behavior of breast cancer subtypes.
Kennecke H; Yerushalmi R; Woods R; Cheang MC; Voduc D; Speers CH; Nielsen TO; Gelmon K
J Clin Oncol; 2010 Jul; 28(20):3271-7. PubMed ID: 20498394
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).
Villacampa G; Pascual T; Brasó-Maristany F; Paré L; Martínez-Sáez O; Cortés J; Ciruelos E; Martin M; Conte P; Carey LA; Fernandez A; Harbeck N; Marín-Aguilera M; Vivancos A; Curigliano G; Villagrasa P; Parker JS; Perou CM; Prat A; Tolaney SM
ESMO Open; 2024 Mar; 9(3):102388. PubMed ID: 38442452
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
9. Patterns of breast cancer relapse in accordance to biological subtype.
Ignatov A; Eggemann H; Burger E; Ignatov T
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1347-1355. PubMed ID: 29675790
[TBL] [Abstract][Full Text] [Related]
10. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
11. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
Buonomo OC; Caredda E; Portarena I; Vanni G; Orlandi A; Bagni C; Petrella G; Palombi L; Orsaria P
PLoS One; 2017; 12(9):e0184680. PubMed ID: 28922402
[TBL] [Abstract][Full Text] [Related]
12. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V; Bras-Maristany F; Dieci MV; Griguolo G; Par L; Mar Ín-Aguilera M; Miglietta F; Bottosso M; Giorgi CA; Blasco P; Castillo O; Galv N P; Vivancos A; Villagrasa P; Parker JS; Perou CM; Conte P; Prat A
EBioMedicine; 2022 Nov; 85():104320. PubMed ID: 36374768
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
[TBL] [Abstract][Full Text] [Related]
15. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
[TBL] [Abstract][Full Text] [Related]
17. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Villacampa G; Tung NM; Pernas S; Paré L; Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Marín-Aguilera M; Brasó-Maristany F; Waks AG; Pascual T; Martínez-Sáez O; Vivancos A; Conte PF; Guarneri V; Vittoria Dieci M; Griguolo G; Cortés J; Llombart-Cussac A; Muñoz M; Vidal M; Adamo B; Wolff AC; DeMichele A; Villagrasa P; Parker JS; Perou CM; Fernandez-Martinez A; Carey LA; Mittendorf EA; Martín M; Prat A; Tolaney SM
Ann Oncol; 2023 Sep; 34(9):783-795. PubMed ID: 37302750
[TBL] [Abstract][Full Text] [Related]
18. Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.
Lim YJ; Lee SW; Choi N; Kwon J; Eom KY; Kang E; Kim EK; Kim SW; Kim JH; Kim YJ; Kim SH; Park SY; Kim JS; Kim IA
Breast Cancer Res Treat; 2017 Jun; 163(3):555-563. PubMed ID: 28315066
[TBL] [Abstract][Full Text] [Related]
19. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Metzger-Filho O; Sun Z; Viale G; Price KN; Crivellari D; Snyder RD; Gelber RD; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Cardoso F
J Clin Oncol; 2013 Sep; 31(25):3083-90. PubMed ID: 23897954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
